|
[1]THOMSON EC, SMITH JA, KLENERMAN P.The natural history of early hepatitis C virus evolution;lessons from a global outbreak in human immunodeficiency virus-1-infected individuals[J].J Gen Virol, 2011, 92 (10) :2227-2236.
|
|
[2]DUAN ZP, JIA ID, HOU J, et al.Current challenges and the management of chronic hepattis C in mainland China[J].JClin Gastroenterol, 2014, 48 (8) :679-686.
|
|
[3]FABRIZI F, MARTIN P, MESSA P.New treatment for hepatitis C in chronic kidney disease, dialysis, and transplant[J].Kidney Int, 2016, 89 (5) :988-994.
|
|
[4]Chinese Society of Hepatology and Chinese Society of Infectious Diseases, Chinese Medical Association.The guideline of prevention and treatment for hepatitis C:A 2015 update[J].JClin Hepatol, 2015, 31 (12) :1961-1979. (in Chinese) 中华医学会肝病学分会, 中华医学会感染病学分会.丙型肝炎防治指南 (2015年更新版) [J].临床肝病杂志, 2015, 31 (12) :1961-1979.
|
|
[5]BORATYN'SKA M, WAKULENKO A, KLINGER M, et al.Chronic allograft dysfunction in kidney transplant recipients:Longterm single-center study[J].Transplant Proc, 2014, 46 (8) :2673-2677.
|
|
[6]MORALES JM, FABRIZI F.Hepatitis C and its impact on renal transplantation[J].Nat Rev Nephrol, 2015, 11 (3) :172-182.
|
|
[7]CHEN GF.Problems and challenges of hepatitis C treatment in the era of direct antiviral drugs[J].J Med Res, 2016, 45 (4) :1-3. (in Chinese) 陈国凤.DAAs时代丙肝治疗的问题与挑战[J].医学研究杂志, 2016, 45 (4) :1-3.
|
|
[8]HE YM, HOU B.PEG-IFNα-2a and ribavirin for decompensated cirrhotic patients with hepatitis C after eliminating complications[J].Clin J Med Offic, 2017, 45 (4) :397-400. (in Chinese) 何妍梅, 侯波.聚乙二醇干扰素α-2a联合利巴韦林治疗失代偿期丙肝肝硬化并发症消除后患者临床观察[J].临床军医杂志, 2017, 45 (4) :397-400.
|
|
[9]WEI F, LIU J, LIU F, et al.Interferon-based anti-viral therapy for hepatitis C virus infection after renal transplantation:An updated meta-analysis[J].PLo S One, 2014, 9 (4) :e90611.
|
|
[10]GAGLIO PJ, MOSS N, MCGAW C, et al.Direct-acting antiviral therapy for hepatitis C:Attitudes regarding future use[J].Dig Dis Sci, 2011, 56 (5) :1509-1515.
|
|
[11]SUDA G, FURUSYO N, TOYODA H, et al.Daclatasvir and asunaprevir in hemodialysis patients with hepatitis C virus infection:A nationwide retrospective study in Japan[J].J Gastroenterol, 2018, 53 (1) :119-128.
|
|
[12]TOYODA H, KUMADA T, TADA T, et al.Safety and efficacy of dual direct-acting antiviral therapy (daclatasvir and asunaprevir) for chronic hepatitis C virus genotype 1 infection in patients on hemodialysis[J].J Gastroenterol, 2016, 51 (7) :741-747.
|
|
[13]KAWAKAMI Y, IMAMURA M, IKEDA H, et al.Pharmacokinetics, efficacy and safety of daclatasvir plus asunaprevir in dialysis patients with chronic hepatitis C:Pilot study[J].J Viral Hepat, 2016, 23 (11) :850-856.
|
|
[14]CARPIO R, PAMUGAS GE, DANGUILAN R, et al.Outcomes of renal allograft recipients with hepatitis C[J].Transplant Proc, 2016, 48 (3) :836-839.
|
|
[15]PAPAYANNIS I, PATEL P.Successful treatment of a hepatitis C positive patient who received kidney transplant from a hepatitis C-positive donor:A case report[J].Prog Transplant, 2016, 26 (3) :238-240.
|
|
[16]SAWINSKI D, KAUR N, AJETI A, et al.Successful treatment of hepatitis C in renal transplant recipients with directacting antiviral agents[J].Am J Transplant, 2016, 16 (5) :1588-1595.
|
|
[17]MAO YJ, ZHANG XF, LIU SD, et al.Efficacy and safety of direct-acting antiviral therapy for hepatitis C after renal transplantation[J].J Shandong Univ:Health Sciences, 2019, 57 (1) :1671-7554. (in Chinese) 卯怡杰, 张旭峰, 刘双德, 等.直接抗病毒治疗肾移植术后丙肝患者的疗效和安全性[J].山东大学学报:医学版, 2019, 57 (1) :1671-7554.
|
|
[18]DENG GG, SHEN S, WU JQ, et al.One case of hepatitis Cvirus cure after renal transplantation:Application of new antiviral drugs[J].Ogran Transplantation, 2017, 8 (3) :229-231. (in Chinese) 邓庚国, 申升, 吴家清, 等.肾移植术后丙型病毒性肝炎治愈1例:新型抗病毒药物的应用[J].器官移植, 2017, 8 (3) :229-231.
|
|
[19]KOSHINO K, USHIGOME H, MASUDA K, et al.Effective treatment with daclatasvir and asunaprevir in kidney transplant patients infected with hepatitis C virus:A report of two cases[J].Transplant Proc, 2017, 49 (5) :1053-1055.
|
DownLoad: